<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595997</url>
  </required_header>
  <id_info>
    <org_study_id>DLX105-003-001-001</org_study_id>
    <nct_id>NCT01595997</nct_id>
  </id_info>
  <brief_title>Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris</brief_title>
  <acronym>2011-00500-15</acronym>
  <official_title>A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delenex Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delenex Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to support the development of a DLX105 topical
      formulation for the indication mild to moderate psoriasis vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability: Investigator's assessment of local tolerability using a validated score for each treatment area. Patient's assessment of subjective tolerability sensations (burning, itching, pain) recorded on a visual analogue scale (VAS) (0-10</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables:</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events Detection of anti-drug antibodies (ADAs). Assessment of immunogenic potential of DLX105 by ELISA with coated DLX105 to capture anti-DLX105 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy variables</measure>
    <time_frame>28 days</time_frame>
    <description>clinical signs of pharmacodynamic activity to intra-dermal administration of DLX105</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild-to-moderate Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DLX105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLX105</intervention_name>
    <description>intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>DLX105</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated Informed Consent

          -  Male or female Caucasian patients with stable chronic mild-to-moderate plaque-type
             psoriasis (PASI ≤15) aged 18-75 years who must have at least two pronounced but not
             active lesions of &gt;9 cm2 each, stable for at least 3 months, local PASI score ≥8.
             Distance between lesions must be at least 30 cm.

          -  Affected body surface area (BSA) ≤10%

          -  Negative pregnancy test for females of child bearing potential (pre-menopausal, &lt;2
             years post-menopausal, not surgically sterile)

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttate psoriasis, palmar, plantar or nail disease) at screening

          -  Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers,
             calcium channel inhibitors or lithium) prior to randomization

          -  Ongoing use of psoriasis treatments (duration of washout, i.e. discontinuation prior
             to randomization):

          -  Alefacept (6 months)

          -  Biological agents other than alefacept, e.g. adalimumab, efalizumab, etanercept,
             infliximab, ustekinumab (12 weeks)

          -  Systemic therapy for psoriasis and psoriatic arthritis (other than above) e.g.
             methotrexate, cyclosporin, fumaric acid (derivatives), systemic steroids (4 weeks)

          -  Photochemotherapy e.g., ultraviolet A with psoralen (PUVA) (4 weeks)

          -  Phototherapy e.g., ultraviolet A (UVA) or ultraviolet B (UVB) (2 weeks)

          -  Topical treatments, except in face, scalp and genital area during screening (2 weeks)

          -  Other investigational psoriasis drugs (4 weeks or 5 half-lives, whichever is longer)

          -  Ongoing use of other (non-psoriasis) treatments (duration of washout, i.e.
             discontinuation prior to randomization):

          -  Investigational drugs, not psoriasis drugs (4 weeks or 5 half-lives, whichever is
             longer)

          -  Known immunosuppression

          -  History or evidence of active tuberculosis. All patients will be tested for
             tuberculosis status using a blood test (QuantiFERON TB-Gold) unless this test has been
             performed within 4 months prior to randomization and was negative. Patients with
             evidence of latent tuberculosis may enter the trial after sufficient treatment has
             been initiated according to local regulations.

          -  Active systemic infections (other than common cold) during the two weeks before
             randomization

          -  Positive test for hepatitis B or C at screening

          -  Positive test for HIV at screening

          -  History or symptoms of malignancy of any organ system (other than history of basal
             cell carcinoma and / or up to three squamous cell carcinomas of the skin, if
             successful treatment has been performed, with no signs of recurrence; actinic
             keratoses, if present at screening, should be treated according to standard therapy
             before randomization), treated or untreated, within the past 5 years, regardless of
             whether there is evidence of local recurrence or metastases.

          -  History of severe hypersensitivity to any human or humanized biological agents

          -  Any severe, progressive or uncontrolled medical condition at baseline that in the
             judgment of the investigator prevents the patient from participating in the study

          -  Any clinically significant abnormal laboratory tests at baseline

          -  Active liver disease with alanine aminotransferase (ALT) and / or aspartate
             aminotransferase (AST) &gt; 3 x upper limit of normal

          -  History of moderate or severe congestive heart failure (New York Heart Association
             [NYHA] class III or IV).

          -  Inability or unwillingness to undergo repeated venipunctures (e.g., due to poor
             tolerability or lack of access to veins)

          -  History or evidence of drug or alcohol abuse within the 6 months prior first study
             drug administration

          -  Patients who had live vaccination within 6 weeks prior first study drug
             administration, or will require live vaccination during the course of the trial

          -  History of hypersensitivity to any of the excipients of the study drug or to
             excipients of similar chemical classes

          -  History of hypersensitivity to any active ingredient of similar chemical entity
             (polypeptides)

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (HCG) laboratory test (&gt; 5 mIU/mL)

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant. UNLESS they are

          -  Women whose partners have been sterilized by vasectomy or other means

          -  Using a highly effective method of birth control (i.e. one that results in a less than
             1% per year failure rate when used consistently and correctly, such as implants,
             injectables, combined oral contraceptives, condoms (by the partner), and some
             intrauterine devices (IUDs)). Periodic abstinence (e.g. calendar, ovulation,
             symptothermal, post-ovulation methods) and withdrawal are not considered acceptable
             forms of birth control within this study.

          -  Reliable contraception should be maintained throughout the study and for 12 weeks
             after the last study drug administration

          -  Participation in any other clinical trial within 4 weeks prior to or during this trial

          -  Exposure to DLX105 / ESBA105 in previous studies of this antibody fragment or in Part
             A of this study (i.e. the same patient cannot participate in Part A and B)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster (UKM)</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into psoriatic lesion of mild-to-moderate psoriatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

